Phase II Clinical Trial Assesses Drug's Safety

September 2011
PN;Sep2011, Vol. 65 Issue 9, p13
Trade Publication
The article focuses on the second Phase II clinical trial of the fast skeletal-muscle troponin activator, CK-2017357 in patients who are suffering from amyotrophic lateral sclerosis (ALS) being performed by Cytokinetics Inc. It states that the clinical trial aims to evaluate the safety and tolerability of CK-2017357 after multiple oral doses to steady state plasma concentrations. Meanwhile, it mentions that the company has no plans to file an investigational new drug application (IND) in 2011.


Related Articles

  • Teva faces trouble over Copaxone.  // PharmaWatch: CNS;Sep2008, Vol. 7 Issue 9, p8 

    The article reports that Teva Pharmaceutical Industries Ltd. is facing trouble on its multiple sclerosis drug, Copaxone, in Israel. The company has been alleged that it tested Copaxone on amyotrophic lateral sclerosis patients despite the failure of the drug in previous trials on mice. The...

  • ALS awareness.Coganeâ„¢ Gets Orphan Drug Status.  // PN;Nov2011, Vol. 65 Issue 11, p21 

    The article reports that Phytopharm PLC drug Coganeâ„¢ was granted the orphan drug status for use in the treatment of amyotrophic lateral sclerosis (ALS) from the U.S. Food and Drug Administration (FDA).

  • New Gene Mutation Discovered.  // PN;Jun2009, Vol. 63 Issue 6, p32 

    The article highlights the discovery of the gene ALS6 by a consortium of scientists funded by the ALS Association (ALSA) in the U.S. The research shows that ALS6 is 5% responsible for cases of inherited amyotrophic lateral sclerosis (ALS). The researchers indicate that the discovery will lead to...

  • Amyotrophic Lateral Sclerosis – A New Role for Old Drugs. Brown, Robert H. // New England Journal of Medicine;3/31/2005, Vol. 352 Issue 13, p1376 

    The article focuses on a study on the potential market value of drugs for diseases caused by molecular physiology of the brain and its disorders. The article states that neurodegenerative diseases are not usually viewed as appropriate targets for drug development by pharmaceutical companies....

  • Bucket Benefits.  // PN;Nov2015, Vol. 69 Issue 11, p40 

    The article presents information on the research announced by the American nonprofit organization, ALS Association on amyotrophic lateral sclerosis (ALS) which is made possible by the ALS Ice Bucket Challenge. The guidance would be submitted to the Food and Drug Administration (FDA) and the...

  • Chapter 16: Clinical Trials in Amyotrophic Lateral Sclerosis. Kaufmann, Petra // Amyotrophic Lateral Sclerosis: A Guide for Patients & Families;2009, p255 

    Chapter 16 of the book "Amyotrophic Lateral Sclerosis: A Guide for Patients and Families," Third Edition, is presented. This chapter deals with issues related to clinical trials of a tentative drug for amyotrophic lateral sclerosis. The importance of clinical trials, the use of placebo controls...

  • ALS Drug Development: Reflections from the Past and a Way Forward Aggarwal, Swati; Cudkowicz, Merit // Neurotherapeutics;Oct2008, Vol. 5 Issue 4, p516 

    Summary: Tremendous advances in our understanding of pathogenesis of amyotrophic lateral sclerosis (ALS) have provided a rich pipeline of drugs for clinical trialists. At least 32 unique compounds have been tested. Nevertheless, riluzole is currently the only treatment that prolongs survival. We...

  • Cellceutix Targeting Head and Neck Cancer with Lead Drug. Boggs, Jennifer // BioWorld Today;6/26/2008, Vol. 19 Issue 124, p1 

    The article focuses on the development efforts of Cellceutix Pharmaceutical Inc. to produce innovative drugs for oncology and inflammatory diseases. A promising drug reportedly developed by this company is called Kevetrin which is said to have resulted to a tumor reduction after its...

  • Genetic Determinants of Amyotrophic Lateral Sclerosis as Therapeutic Targets. Bosco, Daryl A.; Landers, John E. // CNS & Neurological Disorders - Drug Targets;Dec2010, Vol. 9 Issue 6, p779 

    Amyotrophic lateral sclerosis (ALS) is an incurable disease resulting from the deterioration of motor neurons. The onset of disease typically occurs in the fifth decade of life and progresses rapidly; death occurs for 75% of patients within 5 years. The only drug that is available to treat ALS...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics